Visiting Research Agreement Melanoma Therapies

Project Details

Description

As a Physician-researcher, Iris Dirven, the visiting-researcher, will be working in the clinical team of prof. John Haanen. She will learn how to treat patients with cellular therapies, which are becoming increasingly important in the care of solid tumors, and more specifically melanoma. She will therefore work at the AVL/NKI hospital under supervision of the attending oncologists, treat patient that are hospitalized for the treatments, attend multidisciplinary and research discussions. The cellular therapies that are performed there are either reimbursed by the Dutch healthcare system (e.g. TIL in melanoma) or in the context of clinical trials (e.g. Claudin6- CAR-T cell therapies for patients with solid tumours with high Claudin6-expression; TIL therapy in NSCLC). The ultimate goal is to understand and to be able to conduct cellular therapy protocols in a clinical setting and to become acquainted with the side effects and their treatment. This will be of value for the continuation of the PhD-project of Iris Dirven, which includes treatment of melanoma refractory to standard of care treatments.
AcronymAIIFUND147
StatusFinished
Effective start/end date1/05/2530/06/25

Keywords

  • Melanomie Therapies

Flemish discipline codes in use since 2023

  • Other clinical sciences not elsewhere classified